excluding biosimilar studies and excluding studies with more than 5-year gaps in publication between the matches. The statistical analysis and the generation of charts for graphical representation ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of ...

Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US through a private-label agreement with CVS biosimilar subsidiary Cordavis as one of the drivers of its biosimilar business ...

Switching from a trusted medication like Humira to a biosimilar can be challenging for employees, making proactive communication and support critical. Employers should provide clear ...

A Humira biosimilar, produced by drug maker Sandoz, has been given the green light from the US Food and Drug Administration (FDA). Sandoz, a division of Novartis, confirmed that the FDA granted ...

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed.

The lawsuit also claims that JPMorgan allowed Caremark to list its own private label Humira biosimilar as the only option on the formulary for employees, according to a release from Cohen Milstein ...

Alvotech prioritizes maximizing biosimilar HUMIRA’s penetration in U.S. and ... I have a question around interchangeability. Could you compare and contrast the interchangeability and how ...

The VGChartz sales comparison series of articles are updated monthly and each one focuses on a different sales comparison using our estimated video game hardware figures. The charts include ...

It now only private-labels Amgen’s own Humira biosimilar Amjevita (adalimumab-atto). Private-label arrangements, also known as white labeling, are “the latest wrinkle in the biosimilar space ...